NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03691090,Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer,https://clinicaltrials.gov/study/NCT03691090,,COMPLETED,"This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel +cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.",NO,Advanced Esophageal Cancer,DRUG: SHR-1210|DRUG: Placebo|DRUG: paclitaxel|DRUG: cisplatin,"PFS assessed by IRC, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|OS, OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier., approximately 22 months","PFS assessed by investigators, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|6 and 9 month OS rate, OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier., approximately 6 and 9 months|ORR, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|DCR, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|DoR, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|AE, adverse events, approximately 22 months","Antidrug Antibodies (ADAs), To evaluate the incidence of ADAs against SHR-1210, approximately 22 months","Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,596,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",SHR-1210-III-306,2018-12-03,2020-10-30,2022-04-30,2018-10-01,,2022-12-07,"Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, 510060, China",
